The US Food and Drug Administration has approved Arcutis Biotherapeutics’ supplemental new drug application (sNDA) for roflumilast (Zoryve) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2-5 years of…
FDA Approves Roflumilast (Zoryve) Cream 0.05% for Atopic Dermatitis in Children Aged 2-5 Years
